<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp; </B></P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 25%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp; </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp; </B></P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 25%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF
THE<BR>
SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>June 20, 2012 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 25%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ZIOPHARM Oncology, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">Delaware</TD>
    <TD STYLE="width: 2%; vertical-align: bottom; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: top; padding-right: 0.7pt; padding-left: 0.7pt; font-weight: bold; text-align: center">001-33038</TD>
    <TD STYLE="width: 2%; vertical-align: bottom; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">84-1475672</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.7pt; padding-left: 0.7pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or Other Jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of Incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(Commission File Number)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.7pt; padding-left: 0.7pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 66%; vertical-align: top; font-weight: bold; text-align: center"><B>1180 Avenue of the Americas <BR>
20<SUP>th</SUP> Floor<BR>
New York, NY </B></TD>
    <TD STYLE="width: 2%; vertical-align: bottom; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: bottom; font-weight: bold; text-align: center">10036</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(646)&nbsp;214-0700 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not applicable </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 25%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule&nbsp;425 under
the Securities Act (17&nbsp;CFR&nbsp;230.425).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule&nbsp;14a-12 under
the Exchange Act (17&nbsp;CFR&nbsp;240.14a-12).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under
the Exchange Act (17&nbsp;CFR 240.14d-2(b)).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under
the Exchange Act (17&nbsp;CFR 240.13e-4(c)).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;<B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 5.02</B></TD><TD STYLE="text-align: justify"><B>Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ZIOPHARM Oncology, Inc., or the Company,
held its annual meeting of stockholders on June 20, 2012, at which the stockholders approved the ZIOPHARM Oncology, Inc. 2012 Equity
Incentive Plan, which is referred to below as the Plan.<FONT STYLE="color: black"> The following summary of the material features
of the Plan is qualified in its entirety by reference to the complete text of the Plan, which is filed herewith as Exhibit&nbsp;10.1
and incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Types of Awards </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The terms of the Plan provide for the grant
of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation
rights, other stock awards and performance awards that may be settled in cash, stock or other property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Shares Available for Awards </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The aggregate number of shares of common
stock reserved for issuance under the Plan will not exceed 4,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a stock award granted under the Plan
(i) expires or otherwise terminates without all of the shares covered by such stock award having been issued, or (ii) is settled
in cash, such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of common stock
that may be available for issuance under the Plan. If any shares of common stock issued pursuant to a stock award are forfeited
back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares, then
the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. In addition,
any shares of common stock reacquired by the Company in satisfaction of tax withholding obligations on a stock award or as consideration
for the exercise or purchase price of a stock award will again become available for issuance under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of the date of filing of this Form 8-K,
options to purchase 200,000 shares of common stock have been granted, and no shares of common stock have been issued, under the
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Eligibility </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of the Company&rsquo;s employees, non-employee
directors and consultants are eligible to participate in the Plan and may receive all types of awards other than incentive stock
options. Incentive stock options may be granted under the Plan only to employees (including officers) and employees of the Company&rsquo;s
affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Section 162(m) Limits </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Plan, a maximum of 2,000,000 shares
of common stock may be granted to any one participant during any one calendar year pursuant to stock options, stock appreciation
rights and other stock awards whose value is determined by reference to an increase over an exercise price or strike price of at
least 100% of the fair market value of the Company&rsquo;s common stock on the date of grant. In addition, the maximum amount covered
by performance awards that may be granted to any one participant in any one calendar year (whether the grant, vesting or exercise
is contingent upon the attainment during a performance period of the performance goals described below) is 2,000,000 shares of
common stock in the case of performance stock awards and $2,000,000 in the case of performance cash awards. If a performance stock
award is in the form of an option, it will count only against the performance stock award limit. If a performance stock award could
be paid out in cash, it will count only against the performance stock award limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Administration </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Plan is administered by the board of
directors, which may in turn delegate authority to administer the Plan to a committee. The board has delegated authority to administer
the Plan to the compensation committee, but may, at any time, revest in itself some or all of the power previously delegated to
this committee. The compensation committee may make grants of cash and equity awards under the Plan to facilitate compliance with
Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code. Subject to the terms of the Plan, the board or the
compensation committee, each referred to herein as a Plan Administrator, may determine the recipients, numbers and types of awards
to be granted, and the terms and conditions of the awards, including the period of their exercisability and vesting. Subject to
the limitations set forth below, the Plan Administrator also determines the fair market value applicable to a stock award and the
exercise price of stock options and stock appreciation rights granted under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Plan Administrator may also delegate
to one or more of the Company&rsquo;s officers the authority to designate employees who are not officers to be recipients of certain
stock awards and the number of shares subject to such stock awards, provided that the board must specify the total number of shares
of common stock that may be subject to the stock awards granted by such officer, and such officer may not grant a stock award to
himself or herself.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Repricing; Cancellation and Re-Grant
of Stock Awards </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Plan, the board of directors does
not have the authority to reprice any outstanding stock option or stock appreciation right by reducing the exercise price of the
stock option or stock appreciation right or to cancel any outstanding stock option or stock appreciation right that has an exercise
price or strike price in excess of the current fair market value in exchange for cash or other stock awards without obtaining the
approval of the Company&rsquo;s stockholders within 12 months prior to the repricing or cancellation and re-grant event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Stock Options </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock options may be granted under the Plan
pursuant to stock option agreements. The Plan permits the grant of stock options that qualify as incentive stock options, or ISOs,
and nonstatutory stock options, or NSOs. Individual stock option agreements may be more restrictive as to any or all of the permissible
terms described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The exercise price of NSOs may not be less
than 100% of the fair market value of the common stock subject to the stock option on the date of grant. The exercise price of
ISOs may not be less than 100% of the fair market value of the common stock subject to the stock option on the date of grant and,
in some cases, may not be less than 110% of such fair market value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term of stock options granted under
the Plan may not exceed ten years and, in some cases, may not exceed five years. Unless the terms of an optionholder&rsquo;s stock
option agreement or other agreement with the Company provides for earlier or later termination, if an optionholder&rsquo;s service
relationship with the Company, or any of its affiliates, ceases due to death or disability (or the optionholder dies within a certain
period, if any, following cessation of service), the optionholder, or his or her beneficiary, as applicable, may exercise any vested
stock options for up to 12 months after the date the service relationship ends due to the optionholder&rsquo;s disability or up
to 18 months after the date the service relationship ends due to the optionholder&rsquo;s death. Except as otherwise provided in
an applicable stock option agreement or other agreement with the Company, if an optionholder&rsquo;s service relationship with
the Company, or any of its affiliates, is terminated for cause, all stock options held by such optionholder will terminate upon
the date of such optionholder&rsquo;s termination of service, and the optionholder will be prohibited from exercising any stock
option from such termination date. Except as explicitly provided otherwise in an optionholder&rsquo;s stock option agreement or
other agreement with the Company, if an optionholder&rsquo;s service relationship with the Company, or any of its affiliates, ceases
for any other reason, the optionholder may exercise any vested stock options for up to three months after the date the service
relationship ends. Under the Plan, the stock option term may be extended in the event that exercise of the stock option following
termination of service is prohibited by applicable securities laws or if the sale of stock received upon exercise of a stock option
would violate the Company&rsquo;s insider trading policy. In no event may a stock option be exercised after its original expiration
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock options granted under the Plan may
become exercisable in cumulative increments, or &ldquo;vest,&rdquo; as determined by the board of directors at the rate specified
in the stock option agreement. Shares covered by different stock options granted under the Plan may be subject to different vesting
schedules as the board may determine. The board also has flexibility to provide for accelerated vesting of stock awards in certain
events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Restricted Stock Awards </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Restricted stock awards may be granted under
the Plan pursuant to restricted stock award agreements. A restricted stock award may be granted in consideration for cash, check,
bank draft or money order payable to the Company, the recipient&rsquo;s services performed for the Company or an affiliate of the
Company&rsquo;s, or any other form of legal consideration acceptable to the board of directors. Shares of common stock acquired
under a restricted stock award may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined
by the board. Rights to acquire shares of common stock under a restricted stock award may be transferred only upon such terms and
conditions as are set forth in the restricted stock award agreement. Except as otherwise provided in the applicable restricted
stock award agreement, restricted stock awards that have not vested will be forfeited upon the participant&rsquo;s termination
of continuous service for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Restricted Stock Unit Awards
</I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Restricted stock unit awards may be granted
under the Plan pursuant to restricted stock unit award agreements. Payment of any purchase price may be made in any legal form
acceptable to the board of directors. The Company will settle a payment due to a recipient of a restricted stock unit award by
delivery of shares of common stock, by cash, by a combination of cash and stock, or in any other form of consideration determined
by the board and set forth in the restricted stock unit award agreement. Dividend equivalents may be credited in respect of shares
of common stock covered by a restricted stock unit award. Restricted stock unit awards may be subject to vesting in accordance
with a vesting schedule to be determined by the board. Except as otherwise provided in the applicable restricted stock unit award
agreement, restricted stock units that have not vested will be forfeited upon the participant&rsquo;s termination of continuous
service for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Stock Appreciation Rights </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock appreciation rights may be granted
under the Plan pursuant to stock appreciation right agreements. Each stock appreciation right is denominated in common stock share
equivalents. The strike price of each stock appreciation right will be determined by the board of directors but will in no event
be less than 100% of the fair market value of the stock subject to the stock appreciation right at the time of grant. The board
may also impose restrictions or conditions upon the vesting of stock appreciation rights that it deems appropriate. Stock appreciation
rights may be paid in common stock, in cash, in a combination of cash and stock, or in any other form of legal consideration approved
by the board and set forth in the stock appreciation right agreement. Stock appreciation rights will be subject to the same conditions
upon termination and restrictions on transfer as stock options under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Performance Awards </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Plan allows provides for the grant of
cash and stock-based performance awards that may qualify as performance-based compensation that is not subject to the $1 million
limitation on the income tax deductibility of compensation paid per covered employee imposed by Section 162(m) of the Code. Performance
awards may be granted, vest or be exercised based upon the attainment during a specified period of time of specified performance
goals. The length of any performance period, the performance goals to be achieved during the performance period, and the measure
of whether and to what degree such performance goals have been attained will be determined by the performance subcommittee, and/or,
to the extent consistent with Section 162(m) of the Code, the compensation committee or the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In granting a performance award intended
to qualify as &ldquo;performance-based compensation&rdquo; under Section 162(m) of the Code, the performance subcommittee will
set a period of time, or a performance period, over which the attainment of one or more goals, or performance goals, will be measured.
Within the time period prescribed by Section 162(m) of the Code, at a time when the achievement of the performance goals remains
substantially uncertain (typically no later than the earlier of the 90th day of a performance period and the date on which 25%
of the performance period has elapsed), the performance subcommittee will establish the performance goals, based upon one or more
criteria, which is referred to herein as performance criteria, enumerated in the Plan and described below. As soon as administratively
practicable following the end of the performance period, the performance subcommittee will certify in writing whether the performance
goals have been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Performance goals under the Plan will be
based on any one or more of the following performance criteria: (i) earnings (including earnings per share and net earnings); (ii)
earnings before interest, taxes and depreciation; (iii) earnings before interest, taxes, depreciation and amortization; (iv) total
stockholder return; (v) return on equity or average stockholder&rsquo;s equity; (vi) return on assets, investment, or capital employed;
(vii) stock price; (viii) margin (including gross margin); (ix) income (before or after taxes); (x) operating income; (xi) operating
income after taxes; (xii) pre-tax profit; (xiii) operating cash flow; (xiv) sales or revenue targets; (xv) increases in revenue
or product revenue; (xvi) expenses and cost reduction goals; (xvii) improvement in or attainment of working capital levels; (xiii)
economic value added (or an equivalent metric); (xix) market share; (xx) cash flow; (xxi) cash flow per share; (xxii) share price
performance; (xxiii) debt reduction; (xxiv) implementation or completion of projects or processes; (xxv) customer satisfaction;
(xxvi) stockholders&rsquo; equity; (xxvii) capital expenditures; (xxiii) debt levels; (xxix) operating profit or net operating
profit; (xxx) workforce diversity; (xxxi) growth of net income or operating income; (xxxii) billings; (xxxiii) achievement of drug
development milestones; (xxxiv) regulatory achievements, including approval of a compound; (xxxv) progress of internal research
or clinical programs; (xxxvi) progress of partner programs; (xxxvii) implementation or completion of projects and processes; (xxxviii)
clinical progress, (xxxix) in-licensing; and (xl) to the extent that an award is not intended to comply with Section 162(m) of
the Code, other measures of performance selected by the board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Other Stock Awards </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other forms of stock awards valued in whole
or in part with reference to the Company&rsquo;s common stock may be granted either alone or in addition to other stock awards
under the Plan. The board of directors will have sole and complete authority to determine the persons to whom and the time or times
at which such other stock awards will be granted, the number of shares of common stock to be granted and all other conditions of
such other stock awards. Other forms of stock awards may be subject to vesting in accordance with a vesting schedule to be determined
by the board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Clawback Policy </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Awards granted under the Plan will be subject
to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of
any national securities exchange or association on which its securities are listed or as is otherwise required by the Dodd-Frank
Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the board of directors may impose other clawback,
recovery or recoupment provisions in an award agreement as the board determines necessary or appropriate, including a reacquisition
right in respect of previously acquired shares of common stock or other cash or property upon the occurrence of cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Changes to Capital Structure
</I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event of certain capitalization adjustments,
the board of directors will appropriately adjust: (i) the class(es) and maximum number of securities subject to the Plan; (ii)
the class(es) and maximum number of securities that may be issued pursuant to the exercise of ISOs; (iii) the class(es) and maximum
number of securities that may be awarded to any person pursuant to Section 162(m) limits; and (iv) the class(es) and number of
securities and price per share of stock subject to outstanding stock awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Corporate Transactions </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event of a corporate transaction
(as defined in the Plan and described below), the board of directors may have the discretion to take one or more of the following
actions with respect to outstanding stock awards (contingent upon the closing or consummation of such transaction), unless otherwise
provided in the stock award agreement or other written agreement with the participant or unless otherwise provided by the board
at the time of grant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21px; padding-top: 3pt; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-top: 3pt; padding-bottom: 6pt">&bull;</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 6pt">arrange for the surviving or acquiring corporation (or its parent company) to assume or continue the award or to substitute a similar stock award for the award (including an award to acquire the same consideration paid to the Company&rsquo;s stockholders pursuant to the corporate transaction);</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21px; padding-top: 3pt; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-top: 3pt; padding-bottom: 6pt">&bull;</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 6pt">arrange for the assignment of any reacquisition or repurchase rights held by the Company with respect to the stock award to the surviving or acquiring corporation (or its parent company);</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21px; padding-top: 3pt; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-top: 3pt; padding-bottom: 6pt">&bull;</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 6pt">accelerate the vesting, in whole or in part, (and, if applicable, the exercisability) of the stock award and provide for its termination prior to the effective time of the corporate transaction;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21px; padding-top: 3pt; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-top: 3pt; padding-bottom: 6pt">&bull;</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 6pt">arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the award;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21px; padding-top: 3pt; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-top: 3pt; padding-bottom: 6pt; font-size: 10pt">&bull;</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 6pt; font-size: 10pt">cancel or arrange for the cancellation of the stock award, to the extent not vested or exercised prior to the effective time of the corporate transaction, in exchange for such cash consideration, if any, as the board may consider appropriate; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21px; padding-top: 3pt; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-top: 3pt; padding-bottom: 6pt; font-size: 10pt">&bull;</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 6pt; font-size: 10pt">cancel or arrange for the cancellation of the stock award, to the extent not vested or not exercised prior to the effective time of the corporate transaction, in exchange for a payment, in such form as may be determined by the board, equal to the excess, if any, of (i) the value of the property the participant would have received upon the exercise of the stock award immediately prior to the effective time of the corporate transaction, over (ii) any exercise price payable in connection with such exercise.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The board is not obligated to treat all
stock awards or portions of stock awards in the same manner. The board may take different actions with respect to the vested and
unvested portions of a stock award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of the Plan, a corporate transaction
will be deemed to occur in the event of the consummation of (i) a sale or other disposition of all or substantially all of the
Company&rsquo;s consolidated assets, (ii) a sale or other disposition of more than 90% of the Company&rsquo;s outstanding securities,
(iii) a merger, consolidation or similar transaction following which the Company is not the surviving corporation, or (iv) a merger,
consolidation or similar transaction following which the Company is the surviving corporation but the shares of its common stock
outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Change in Control </I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Plan, a stock award may be subject
to additional acceleration of vesting and exercisability upon or after a change in control (as defined in the Plan) as may be provided
in the stock award agreement or other written agreement with the participant, but in the absence of such provision, no such acceleration
will occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Plan Amendments and Termination
</I></B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The board of directors will have the authority
to amend or terminate the Plan at any time. However, except as otherwise provided in the Plan, no amendment or termination of the
Plan may materially impair any rights under awards already granted to a participant unless agreed to by the affected participant.
The Company will obtain stockholder approval of any amendment to the Plan as required by applicable law and listing requirements.
No ISOs may be granted under the Plan after the tenth anniversary of March 7, 2012, which was the date the Plan was adopted by
the board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The form of restricted stock agreement and
the form of option agreement under the Plan are filed herewith as Exhibit 10.2 and Exhibit 10.3, respectively, and incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>Item 5.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Submission of Matters
to a Vote of Security Holders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the Company&rsquo;s annual meeting of
stockholders on June 20, 2012, all proposals brought before the meeting and requiring approval were approved by the requisite vote,
and the votes with respect to each proposal are set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)&#9;The stockholders elected eight directors
to serve as members of the Company&rsquo;s board of directors until the next annual meeting of the stockholders. The stockholders
present in person or by proxy cast the following numbers of votes in connection with the election of directors, resulting in the
election of all director nominees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding-right: 0; padding-left: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">Nominee</P></TD>
    <TD STYLE="width: 27%; padding-right: 0; padding-left: 0; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center">Votes
        For</P></TD>
    <TD STYLE="width: 28%; padding-right: 0; padding-left: 0; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center">Votes
        Withheld</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">Jonathan Lewis</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">46,178,362</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">&nbsp;&nbsp;&nbsp;783,799</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">Richard E. Bagley</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">44,660,364</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">2,301,797</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">Murray Brennan</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">45,885,317</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">1,076,844</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">James A. Cannon</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">45,874,412</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">1,087,749</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">Wyche Fowler, Jr.</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">45,863,838</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">1,098,323</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">Randal J. Kirk</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">38,651,464</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">8,310,697</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">Timothy McInerney</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">45,020,503</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">1,941,658</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">Michael Weiser</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">45,308,808</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center">1,653,353</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: black; background-color: white">The
stockholders adopted the Company&rsquo;s 2012 Equity Incentive Plan. There were 42,419,710 votes cast for the proposal; 4,462,673
votes were cast against the proposal; 79,778 votes abstained; and there were 19,760,382 broker non-votes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: black; background-color: white">The
stockholders ratified the appointment of McGladrey &amp; Pullen, LLP as the independent registered public accounting firm of the
Company for 2012.&nbsp;&nbsp;There were 66,311,395 votes cast for the proposal; 374,010 votes were cast against the proposal; 37,138
votes abstained; and there were no broker non-votes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
stockholders approved, on an advisory basis, the compensation of the Company&rsquo;s named executive officers, as disclosed in
the Company&rsquo;s proxy statement for the 2012 annual meeting. There were 45,416,124 votes cast for the proposal; 1,364,381 votes
were cast against the proposal; 181,656 votes abstained; and there were 19,760,382 broker non-votes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and
Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Exhibits</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; padding: 0.75pt 0.75pt 0.75pt 0; font-weight: bold">Exhibit No.</TD>
    <TD STYLE="width: 86%; padding: 0.75pt 0.75pt 0.75pt 0; font-weight: bold; text-align: center">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">10.1</TD>
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">10.2</TD>
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">Form of Restricted Stock Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">10.3</TD>
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">Form of Option Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SIGNATURES </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">ZIOPHARM Oncology, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">By:</TD>
    <TD STYLE="width: 49%; border-bottom: windowtext 1pt solid; padding-left: 10pt; text-align: justify; text-indent: -10pt">/s/ Caesar Belbel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Date: June 26, 2012</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: Caesar Belbel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Title: Executive Vice President, Chief Legal Officer and Secretary</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX OF EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; padding: 0.75pt 0.75pt 0.75pt 0; font-weight: bold">Exhibit No.</TD>
    <TD STYLE="width: 86%; padding: 0.75pt 0.75pt 0.75pt 0; font-weight: bold; text-align: center">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">10.1</TD>
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">10.2</TD>
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">Form of Restricted Stock Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">10.3</TD>
    <TD STYLE="padding: 0.75pt 0.75pt 0.75pt 0">Form of Option Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v316803_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 59900}]
{"company-data": {"conformed-name": "ZIOPHARM ONCOLOGY INC", "cik": "0001107421", "assigned-sic": "8093", "irs-number": "841475642", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33038", "film-number": "12927493"}, "business-address": {"street1": "1180 AVENUE OF THE AMERICA", "street2": "19TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10036", "phone": "646-214-0700"}, "mail-address": {"street1": "1180 AVENUE OF THE AMERICA", "street2": "19TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10036"}, "former-company": {"former-conformed-name": "EASYWEB INC", "date-changed": "20010213"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
June 20, 2012
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
001-33038
84-1475672
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
1180 Avenue of the Americas
20
th
Floor
New York, NY
10036
(Address of Principal Executive Offices)
(Zip Code)
(646) 214-0700
(Registrant's telephone number, including
area code)
Not applicable
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425).
o
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)).
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)).
Item 5.02
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
ZIOPHARM Oncology, Inc., or the Company,
held its annual meeting of stockholders on June 20, 2012, at which the stockholders approved the ZIOPHARM Oncology, Inc. 2012 Equity
Incentive Plan, which is referred to below as the Plan.
The following summary of the material features
of the Plan is qualified in its entirety by reference to the complete text of the Plan, which is filed herewith as Exhibit 10.1
and incorporated herein by reference.
Types of Awards
The terms of the Plan provide for the grant
of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation
rights, other stock awards and performance awards that may be settled in cash, stock or other property.
Shares Available for Awards
The aggregate number of shares of common
stock reserved for issuance under the Plan will not exceed 4,000,000 shares.
If a stock award granted under the Plan
(i) expires or otherwise terminates without all of the shares covered by such stock award having been issued, or (ii) is settled
in cash, such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of common stock
that may be available for issuance under the Plan. If any shares of common stock issued pursuant to a stock award are forfeited
back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares, then
the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. In addition,
any shares of common stock reacquired by the Company in satisfaction of tax withholding obligations on a stock award or as consideration
for the exercise or purchase price of a stock award will again become available for issuance under the Plan.
As of the date of filing of this Form 8-K,
options to purchase 200,000 shares of common stock have been granted, and no shares of common stock have been issued, under the
Plan.
Eligibility
All of the Company's employees, non-employee
directors and consultants are eligible to participate in the Plan and may receive all types of awards other than incentive stock
options. Incentive stock options may be granted under the Plan only to employees (including officers) and employees of the Company's
affiliates.
Section 162(m) Limits
Under the Plan, a maximum of 2,000,000 shares
of common stock may be granted to any one participant during any one calendar year pursuant to stock options, stock appreciation
rights and other stock awards whose value is determined by reference to an increase over an exercise price or strike price of at
least 100% of the fair market value of the Company's common stock on the date of grant. In addition, the maximum amount covered
by performance awards that may be granted to any one participant in any one calendar year (whether the grant, vesting or exercise
is contingent upon the attainment during a performance period of the performance goals described below) is 2,000,000 shares of
common stock in the case of performance stock awards and $2,000,000 in the case of performance cash awards. If a performance stock
award is in the form of an option, it will count only against the performance stock award limit. If a performance stock award could
be paid out in cash, it will count only against the performance stock award limit.
Administration
The Plan is administered by the board of
directors, which may in turn delegate authority to administer the Plan to a committee. The board has delegated authority to administer
the Plan to the compensation committee, but may, at any time, revest in itself some or all of the power previously delegated to
this committee. The compensation committee may make grants of cash and equity awards under the Plan to facilitate compliance with
Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code. Subject to the terms of the Plan, the board or the
compensation committee, each referred to herein as a Plan Administrator, may determine the recipients, numbers and types of awards
to be granted, and the terms and conditions of the awards, including the period of their exercisability and vesting. Subject to
the limitations set forth below, the Plan Administrator also determines the fair market value applicable to a stock award and the
exercise price of stock options and stock appreciation rights granted under the Plan.
The Plan Administrator may also delegate
to one or more of the Company's officers the authority to designate employees who are not officers to be recipients of certain
stock awards and the number of shares subject to such stock awards, provided that the board must specify the total number of shares
of common stock that may be subject to the stock awards granted by such officer, and such officer may not grant a stock award to
himself or herself.
Repricing; Cancellation and Re-Grant
of Stock Awards
Under the Plan, the board of directors does
not have the authority to reprice any outstanding stock option or stock appreciation right by reducing the exercise price of the
stock option or stock appreciation right or to cancel any outstanding stock option or stock appreciation right that has an exercise
price or strike price in excess of the current fair market value in exchange for cash or other stock awards without obtaining the
approval of the Company's stockholders within 12 months prior to the repricing or cancellation and re-grant event.
Stock Options
Stock options may be granted under the Plan
pursuant to stock option agreements. The Plan permits the grant of stock options that qualify as incentive stock options, or ISOs,
and nonstatutory stock options, or NSOs. Individual stock option agreements may be more restrictive as to any or all of the permissible
terms described below.
The exercise price of NSOs may not be less
than 100% of the fair market value of the common stock subject to the stock option on the date of grant. The exercise price of
ISOs may not be less than 100% of the fair market value of the common stock subject to the stock option on the date of grant and,
in some cases, may not be less than 110% of such fair market value.
The term of stock options granted under
the Plan may not exceed ten years and, in some cases, may not exceed five years. Unless the terms of an optionholder's stock
option agreement or other agreement with the Company provides for earlier or later termination, if an optionholder's service
relationship with the Company, or any of its affiliates, ceases due to death or disability (or the optionholder dies within a certain
period, if any, following cessation of service), the optionholder, or his or her beneficiary, as applicable, may exercise any vested
stock options for up to 12 months after the date the service relationship ends due to the optionholder's disability or up
to 18 months after the date the service relationship ends due to the optionholder's death. Except as otherwise provided in
an applicable stock option agreement or other agreement with the Company, if an optionholder's service relationship with
the Company, or any of its affiliates, is terminated for cause, all stock options held by such optionholder will terminate upon
the date of such optionholder's termination of service, and the optionholder will be prohibited from exercising any stock
option from such termination date. Except as explicitly provided otherwise in an optionholder's stock option agreement or
other agreement with the Company, if an optionholder's service relationship with the Company, or any of its affiliates, ceases
for any other reason, the optionholder may exercise any vested stock options for up to three months after the date the service
relationship ends. Under the Plan, the stock option term may be extended in the event that exercise of the stock option following
termination of service is prohibited by applicable securities laws or if the sale of stock received upon exercise of a stock option
would violate the Company's insider trading policy. In no event may a stock option be exercised after its original expiration
date.
Stock options granted under the Plan may
become exercisable in cumulative increments, or "vest," as determined by the board of directors at the rate specified
in the stock option agreement. Shares covered by different stock options granted under the Plan may be subject to different vesting
schedules as the board may determine. The board also has flexibility to provide for accelerated vesting of stock awards in certain
events.
Restricted Stock Awards
Restricted stock awards may be granted under
the Plan pursuant to restricted stock award agreements. A restricted stock award may be granted in consideration for cash, check,
bank draft or money order payable to the Company, the recipient's services performed for the Company or an affiliate of the
Company's, or any other form of legal consideration acceptable to the board of directors. Shares of common stock acquired
under a restricted stock award may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined
by the board. Rights to acquire shares of common stock under a restricted stock award may be transferred only upon such terms and
conditions as are set forth in the restricted stock award agreement. Except as otherwise provided in the applicable restricted
stock award agreement, restricted stock awards that have not vested will be forfeited upon the participant's termination
of continuous service for any reason.
Restricted Stock Unit Awards
Restricted stock unit awards may be granted
under the Plan pursuant to restricted stock unit award agreements. Payment of any purchase price may be made in any legal form
acceptable to the board of directors. The Company will settle a payment due to a recipient of a restricted stock unit award by
delivery of shares of common stock, by cash, by a combination of cash and stock, or in any other form of consideration determined
by the board and set forth in the restricted stock unit award agreement. Dividend equivalents may be credited in respect of shares
of common stock covered by a restricted stock unit award. Restricted stock unit awards may be subject to vesting in accordance
with a vesting schedule to be determined by the board. Except as otherwise provided in the applicable restricted stock unit award
agreement, restricted stock units that have not vested will be forfeited upon the participant's termination of continuous
service for any reason.
Stock Appreciation Rights
Stock appreciation rights may be granted
under the Plan pursuant to stock appreciation right agreements. Each stock appreciation right is denominated in common stock share
equivalents. The strike price of each stock appreciation right will be determined by the board of directors but will in no event
be less than 100% of the fair market value of the stock subject to the stock appreciation right at the time of grant. The board
may also impose restrictions or conditions upon the vesting of stock appreciation rights that it deems appropriate. Stock appreciation
rights may be paid in common stock, in cash, in a combination of cash and stock, or in any other form of legal consideration approved
by the board and set forth in the stock appreciation right agreement. Stock appreciation rights will be subject to the same conditions
upon termination and restrictions on transfer as stock options under the Plan.
Performance Awards
The Plan allows provides for the grant of
cash and stock-based performance awards that may qualify as performance-based compensation that is not subject to the $1 million
limitation on the income tax deductibility of compensation paid per covered employee imposed by Section 162(m) of the Code. Performance
awards may be granted, vest or be exercised based upon the attainment during a specified period of time of specified performance
goals. The length of any performance period, the performance goals to be achieved during the performance period, and the measure
of whether and to what degree such performance goals have been attained will be determined by the performance subcommittee, and/or,
to the extent consistent with Section 162(m) of the Code, the compensation committee or the board of directors.
In granting a performance award intended
to qualify as "performance-based compensation" under Section 162(m) of the Code, the performance subcommittee will
set a period of time, or a performance period, over which the attainment of one or more goals, or performance goals, will be measured.
Within the time period prescribed by Section 162(m) of the Code, at a time when the achievement of the performance goals remains
substantially uncertain (typically no later than the earlier of the 90th day of a performance period and the date on which 25%
of the performance period has elapsed), the performance subcommittee will establish the performance goals, based upon one or more
criteria, which is referred to herein as performance criteria, enumerated in the Plan and described below. As soon as administratively
practicable following the end of the performance period, the performance subcommittee will certify in writing whether the performance
goals have been satisfied.
Performance goals under the Plan will be
based on any one or more of the following performance criteria: (i) earnings (including earnings per share and net earnings); (ii)
earnings before interest, taxes and depreciation; (iii) earnings before interest, taxes, depreciation and amortization; (iv) total
stockholder return; (v) return on equity or average stockholder's equity; (vi) return on assets, investment, or capital employed;
(vii) stock price; (viii) margin (including gross margin); (ix) income (before or after taxes); (x) operating income; (xi) operating
income after taxes; (xii) pre-tax profit; (xiii) operating cash flow; (xiv) sales or revenue targets; (xv) increases in revenue
or product revenue; (xvi) expenses and cost reduction goals; (xvii) improvement in or attainment of working capital levels; (xiii)
economic value added (or an equivalent metric); (xix) market share; (xx) cash flow; (xxi) cash flow per share; (xxii) share price
performance; (xxiii) debt reduction; (xxiv) implementation or completion of projects or processes; (xxv) customer satisfaction;
(xxvi) stockholders' equity; (xxvii) capital expenditures; (xxiii) debt levels; (xxix) operating profit or net operating
profit; (xxx) workforce diversity; (xxxi) growth of net income or operating income; (xxxii) billings; (xxxiii) achievement of drug
development milestones; (xxxiv) regulatory achievements, including approval of a compound; (xxxv) progress of internal research
or clinical programs; (xxxvi) progress of partner programs; (xxxvii) implementation or completion of projects and processes; (xxxviii)
clinical progress, (xxxix) in-licensing; and (xl) to the extent that an award is not intended to comply with Section 162(m) of
the Code, other measures of performance selected by the board.
Other Stock Awards
Other forms of stock awards valued in whole
or in part with reference to the Company's common stock may be granted either alone or in addition to other stock awards
under the Plan. The board of directors will have sole and complete authority to determine the persons to whom and the time or times
at which such other stock awards will be granted, the number of shares of common stock to be granted and all other conditions of
such other stock awards. Other forms of stock awards may be subject to vesting in accordance with a vesting schedule to be determined
by the board.
Clawback Policy
Awards granted under the Plan will be subject
to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of
any national securities exchange or association on which its securities are listed or as is otherwise required by the Dodd-Frank
Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the board of directors may impose other clawback,
recovery or recoupment provisions in an award agreement as the board determines necessary or appropriate, including a reacquisition
right in respect of previously acquired shares of common stock or other cash or property upon the occurrence of cause.
Changes to Capital Structure
In the event of certain capitalization adjustments,
the board of directors will appropriately adjust: (i) the class(es) and maximum number of securities subject to the Plan; (ii)
the class(es) and maximum number of securities that may be issued pursuant to the exercise of ISOs; (iii) the class(es) and maximum
number of securities that may be awarded to any person pursuant to Section 162(m) limits; and (iv) the class(es) and number of
securities and price per share of stock subject to outstanding stock awards.
Corporate Transactions
In the event of a corporate transaction
(as defined in the Plan and described below), the board of directors may have the discretion to take one or more of the following
actions with respect to outstanding stock awards (contingent upon the closing or consummation of such transaction), unless otherwise
provided in the stock award agreement or other written agreement with the participant or unless otherwise provided by the board
at the time of grant:
•
arrange for the surviving or acquiring corporation (or its parent company) to assume or continue the award or to substitute a similar stock award for the award (including an award to acquire the same consideration paid to the Company's stockholders pursuant to the corporate transaction);
•
arrange for the assignment of any reacquisition or repurchase rights held by the Company with respect to the stock award to the surviving or acquiring corporation (or its parent company);
•
accelerate the vesting, in whole or in part, (and, if applicable, the exercisability) of the stock award and provide for its termination prior to the effective time of the corporate transaction;
•
arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the award;
•
cancel or arrange for the cancellation of the stock award, to the extent not vested or exercised prior to the effective time of the corporate transaction, in exchange for such cash consideration, if any, as the board may consider appropriate; and
•
cancel or arrange for the cancellation of the stock award, to the extent not vested or not exercised prior to the effective time of the corporate transaction, in exchange for a payment, in such form as may be determined by the board, equal to the excess, if any, of (i) the value of the property the participant would have received upon the exercise of the stock award immediately prior to the effective time of the corporate transaction, over (ii) any exercise price payable in connection with such exercise.
The board is not obligated to treat all
stock awards or portions of stock awards in the same manner. The board may take different actions with respect to the vested and
unvested portions of a stock award.
For purposes of the Plan, a corporate transaction
will be deemed to occur in the event of the consummation of (i) a sale or other disposition of all or substantially all of the
Company's consolidated assets, (ii) a sale or other disposition of more than 90% of the Company's outstanding securities,
(iii) a merger, consolidation or similar transaction following which the Company is not the surviving corporation, or (iv) a merger,
consolidation or similar transaction following which the Company is the surviving corporation but the shares of its common stock
outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction.
Change in Control
Under the Plan, a stock award may be subject
to additional acceleration of vesting and exercisability upon or after a change in control (as defined in the Plan) as may be provided
in the stock award agreement or other written agreement with the participant, but in the absence of such provision, no such acceleration
will occur.
Plan Amendments and Termination
The board of directors will have the authority
to amend or terminate the Plan at any time. However, except as otherwise provided in the Plan, no amendment or termination of the
Plan may materially impair any rights under awards already granted to a participant unless agreed to by the affected participant.
The Company will obtain stockholder approval of any amendment to the Plan as required by applicable law and listing requirements.
No ISOs may be granted under the Plan after the tenth anniversary of March 7, 2012, which was the date the Plan was adopted by
the board.
The form of restricted stock agreement and
the form of option agreement under the Plan are filed herewith as Exhibit 10.2 and Exhibit 10.3, respectively, and incorporated
herein by reference.
Item 5.07           Submission of Matters
to a Vote of Security Holders.
At the Company's annual meeting of
stockholders on June 20, 2012, all proposals brought before the meeting and requiring approval were approved by the requisite vote,
and the votes with respect to each proposal are set forth below.
(i)	The stockholders elected eight directors
to serve as members of the Company's board of directors until the next annual meeting of the stockholders. The stockholders
present in person or by proxy cast the following numbers of votes in connection with the election of directors, resulting in the
election of all director nominees:
Nominee
Votes
        For
Votes
        Withheld
Jonathan Lewis
46,178,362
783,799
Richard E. Bagley
44,660,364
2,301,797
Murray Brennan
45,885,317
1,076,844
James A. Cannon
45,874,412
1,087,749
Wyche Fowler, Jr.
45,863,838
1,098,323
Randal J. Kirk
38,651,464
8,310,697
Timothy McInerney
45,020,503
1,941,658
Michael Weiser
45,308,808
1,653,353
(ii)
The
stockholders adopted the Company's 2012 Equity Incentive Plan. There were 42,419,710 votes cast for the proposal; 4,462,673
votes were cast against the proposal; 79,778 votes abstained; and there were 19,760,382 broker non-votes.
(iii)
The
stockholders ratified the appointment of McGladrey & Pullen, LLP as the independent registered public accounting firm of the
Company for 2012.  There were 66,311,395 votes cast for the proposal; 374,010 votes were cast against the proposal; 37,138
votes abstained; and there were no broker non-votes.
(iv)      The
stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in
the Company's proxy statement for the 2012 annual meeting. There were 45,416,124 votes cast for the proposal; 1,364,381 votes
were cast against the proposal; 181,656 votes abstained; and there were 19,760,382 broker non-votes.
Item 9.01            Financial Statements and
Exhibits
(d)
Exhibits
.
Exhibit No.
Description
10.1
ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan
10.2
Form of Restricted Stock Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan
10.3
Form of Option Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
ZIOPHARM Oncology, Inc.
By:
/s/ Caesar Belbel
Date: June 26, 2012
Name: Caesar Belbel
Title: Executive Vice President, Chief Legal Officer and Secretary
INDEX OF EXHIBITS
Exhibit No.
Description
10.1
ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan
10.2
Form of Restricted Stock Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan
10.3
Form of Option Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan